Results of a Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Mexidol in Prolonged Sequential Therapy of Patients in th... by Stakhovskaya, L. V., Shamalov, N. A., Khasanova, D. R., Mel’nikova, E. V., Agaf’ina, A. S., Golikov, K. V., Bogdanov, E. I., Yakupova, A. A., Roshkovskaya, L. V., Lukinykh, L. V., Lokshtanova, T. M., Poverennova, I. E., Shchepankevich, L. A.

Get full text

Parasomnias Associated with Disordered Arousal from Slow-Wave Sleep: Mechanism of Occurrence and Neurophysiological Characteristics by Zakharov, A. V., Poverennova, I. E., Kalinin, V. A., Khivintseva, E. V.

Get full text

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial by Gold, Ralf, Prof, Giovannoni, Gavin, Prof, Selmaj, Krzysztof, Prof, Havrdova, Eva, Prof, Montalban, Xavier, Prof, Radue, Ernst-Wilhelm, Prof, Stefoski, Dusan, MD, Robinson, Randy, PhD, Riester, Katherine, MPH, Rana, Jitesh, MD, Elkins, Jacob, MD, O'Neill, Gilmore, MRCPI

Get full text

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial by Giovannoni, Gavin, Prof, Gold, Ralf, Prof, Selmaj, Krzysztof, Prof, Havrdova, Eva, Prof, Montalban, Xavier, Prof, Radue, Ernst-Wilhelm, Prof, Stefoski, Dusan, MD, McNeill, Manjit, MSc, Amaravadi, Lakshmi, PhD, Sweetser, Marianne, MD, Elkins, Jacob, MD, O'Neill, Gilmore, MRCPI

Get full text

Functional prognosis of acute ischemic stroke patients from their neuropsychological features by Repina, Lydia A., Romanova, Tatiana V., Poverennova, Irina E., Persteneva, Natalya P.

Get full text

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study by Montalban, Xavier, Leist, Thomas P, Cohen, Bruce A, Moses, Harold, Campbell, Jackie, Hicking, Christine, Dangond, Fernando, Comi, Giancarlo, Gallo, Paolo, Pozzilli, Carlo, Gasperini, Claudio, Morra, Vincenzo Brescia, Boyko, Alexey N, Amelina, Olga, Kotov, Sergey V, Novikova, Lilia, Patrusheva, Olga, Zavalishin, Igor, Khabirov, Farid, Maslova, Natalia, Malkova, Nadezda, Poverennova, Irina E, Montalban, Xavier, Martinez Yelamos, Sergio, Izquierdo, Guillermo, Fernandez, Oscar, Rodriguez-Antiguedad, Alfredo, Sempere, Angel Perez, Arroyo, Rafael, Casanova, Bonaventura, Arias, Manual, Cascione, Mark, Cohen, Bruce Arnold, Fox, Edward, Berkovich, Regina, Kaufman, Michael, Leist, Thomas, Jacobs, Dina, Miller, Tamara, Racke, Michael, Hutton, George, Singer, Barry, Kresa-Reahl, Kiren, Pharr, Emily, Carter, Jonathan L, Wendt, Jeanette, Tandan, Rup, Bomprezzi, Roberto, Ford, Corey, Kamin, Stephen, Pless, Misha, Garmany, George P, Gazda, Suzanne, English, Jeffrey, Green, Barbara, Garwacki, Dennis, Gould, Jeffrey, LaGanke, Chris

Get full text

Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results by Giovannoni, G, Barbarash, O, Casset-Semanaz, F, King, J, Metz, L, Pardo, G, Simsarian, J, Sørensen, PS, Stubinski, B

Get full text

Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing—remitting multiple sclerosis by De Stefano, Nicola, Curtin, François, Stubinski, Bettina, Blevins, Gregg, Drulovic, Jelena, Issard, Delphine, Shotekov, Penko, Gasperini, Claudio, IMPROVE study investigators

Get full text

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results by Giovannoni, G, Barbarash, O, Casset-Semanaz, F, King, J, Metz, L, Pardo, G, Simsarian, J, Sørensen, P S, Stubinski, B

Get full text